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Summary
 
We have previously shown that transgenic mice expressing the oncoprotein v-Rel under the
control of a T cell–specific promoter develop T cell lymphomas. Tumor formation was corre-
lated with the presence of p50/v-Rel and v-Rel/v-Rel nuclear 
 
k
 
B-binding activity. Since ex-
perimental evidence has led to the suggestion of a potential tumor suppressor activity for I
 
k
 
B
 
a
 
,
we have studied the role of I
 
k
 
B
 
a
 
 in the transforming activity of v-Rel by overexpressing I
 
k
 
B
 
a
 
in v-
 
rel
 
 transgenic mice. Overexpression of I
 
k
 
B
 
a
 
 in v-
 
rel
 
 transgenic mice resulted in an ex-
tended survival, and the development of cutaneous T cell lymphomas of CD8
 
1
 
CD4
 
2
 
 pheno-
type. These phenotypic alterations were associated with a dramatic reduction of p50/v-Rel,
but not v-Rel/v-Rel nuclear DNA binding activity and an increased expression of the inter-
cellular adhesion molecule 1. Our results indicate that v-Rel homodimers are active in trans-
formation and that the capacity of v-Rel–containing complexes to escape the inhibitory effect
of I
 
k
 
B
 
a
 
 may be a key element in its transforming capability.
 
T
 
he oncogene v-
 
rel
 
 was originally identified as the
transforming component of the avian retrovirus retic-
uloendotheliosis virus T. v-Rel induces neoplastic disease
in birds, and compared to c-Rel, is missing 2 NH
 
2
 
-terminal
and 118 COOH-terminal amino acids, and has several in-
ternal changes (1–5). v-Rel is a member of the Rel/NF-
 
k
 
B
family of eukaryotic transcription factors, which includes
c-Rel, RelA (p65), RelB, NF-
 
k
 
B1 (p50/p105), NF-
 
k
 
B2
(p52/p100), and the 
 
Drosophila
 
 proteins Dorsal, dorsal-
related immunity factor, and Relish (6–12).
The finding that v-Rel and the corresponding protoon-
cogene c-Rel are members of the Rel/NF-
 
k
 
B transcrip-
tion factor family led to the suggestion that transformation
resulted from v-Rel–induced changes in gene expression
(1–5). Rel/NF-
 
k
 
B proteins are related through an 
 
z
 
300–
amino acid NH
 
2
 
-terminal region known as the Rel homol-
ogy domain (RHD)
 
1
 
, which contains sequences important
for dimerization, DNA binding, inhibitor binding, and nu-
clear localization. The activity of Rel/NF-
 
k
 
B complexes is
modulated by their interaction with the I
 
k
 
B family of in-
hibitors, which contain ankyrin repeats. In unstimulated
cells, Rel/NF-
 
k
 
B dimers remain in the cytoplasm as inac-
tive complexes through association with I
 
k
 
B molecules
that mask their nuclear localization signals. A wide variety
of stimuli result in the rapid phosphorylation and degrada-
tion of I
 
k
 
B molecules and nuclear translocation of Rel/
NF-
 
k
 
B complexes (6–16).
The mechanism by which v-Rel induces oncogenic
transformation is not clear, and it was originally believed
that v-Rel could only transform avian cells (1–5). Re-
cently, we demonstrated that v-Rel also has the capacity of
transforming mammalian cells in vivo. Transgenic mice ex-
pressing v-Rel in thymocytes develop T cell lymphomas
with very poor prognosis. In tumor cells from v-Rel trans-
genic mice, there are two major DNA-binding complexes
containing v-Rel homodimers and p50/v-Rel heterodimers.
However, when v-
 
rel
 
 transgenic mice were crossed with
p50-deficient animals, T cell leukemia appeared at an ear-
lier stage, suggesting that the v-Rel homodimer is the es-
sential transforming complex (17).
In this report we address the question of whether over-
expression of the inhibitory I
 
k
 
B
 
a
 
 protein, which has been
suggested to have tumor suppresser activity (18), can re-
verse the transforming activity of v-Rel in v-
 
rel
 
 transgenic
mice. Overexpression of I
 
k
 
B
 
a
 
 extended the survival of
v-
 
rel
 
 transgenic mice and reduced the severity of lympho-
mas. Surprisingly, I
 
k
 
B
 
a
 
 overexpression resulted in a change
in the clinical expression of the disease with an expansion
of CD8
 
1
 
CD4
 
2
 
 T cells in peripheral tissues. These T cell
changes were associated with increased levels in the expres-
sion of the intercellular adhesion molecule 1 (ICAM-1),
 
1
 
Abbreviations used in this paper:
 
 EMSA, electrophoretic mobility shift assay;
ICAM-1, intercellular adhesion molecule 1; mRNA, messenger RNA;
RHD, Rel homology domain.
 
These studies were performed according to guidelines established by the
Bristol-Myers Squibb Animal Care and Use Committee.
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increased dermotropism and the development of cutaneous
lymphoma. T cells from v-
 
rel/ikba
 
 double transgenic mice
presented a dramatic reduction of p50/v-Rel but not of
v-Rel/v-Rel nuclear DNA-binding activity. Our results
indicate that v-Rel homodimers are active in transforma-
tion and that v-Rel containing complexes have an intrinsic
capability to escape the inhibitory effect of I
 
k
 
B
 
a
 
. We pos-
tulate that variations in the clinical expression of related
lymphoid malignancies may reflect subtle changes in the
nuclear composition and interplay among different Rel/
NF-
 
k
 
B and I
 
k
 
B molecules.
 
Materials and Methods
 
Plasmid Construction and Generation of Transgenic Mice.
 
The gen-
eration of v-
 
rel
 
 transgenic mice has been previously described
(17). A detailed description of the generation and characterization
of 
 
ikba
 
 transgenic mice will be reported elsewhere (Perez, P., un-
published observations). Screening of I
 
k
 
B
 
a
 
 transgenic mice was
performed as described (19), and line 1 was selected for its high
level of expression as determined by immunoblot analysis using a
mouse monoclonal I
 
k
 
B
 
a
 
 antibody. To generate double v-
 
rel
 
/
 
ikba
 
transgenic mice, 
 
ikba
 
 transgenic mice were bred to homozygocity
and crossed with heterozygote v-
 
rel
 
 transgenic animals. The mice
obtained from these intercrosses were screened by PCR using a
pair of specific v-
 
rel
 
 oligonucleotides: 5
 
9
 
-TTTCTCACCAAC-
CTCCGATTCACTG-3
 
9
 
 and 5
 
9
 
-ATCTCTGCAGCCTTTTC-
CAACTAGA-3
 
9
 
.
 
Histopathology and Immunofluorescence.
 
Mice were killed and
tissues were immersion fixed in 10% buffered formalin. Tissues
were embedded in paraffin blocks and processed by routine
methods, sectioned at 5–10-
 
m
 
m thickness, stained with hematox-
ylin and eosin, and examined by light microscopy. Single cell sus-
pensions from tumor-bearing spleens were prepared according to
standard procedures and spun onto slides as previously described
(20). For immunofluorescence, the cytospins were incubated at
4
 
8
 
C overnight with anti–v-Rel or anti-I
 
k
 
B
 
a
 
 polyclonal antibod-
ies. Anti–v-Rel and anti-I
 
k
 
B
 
a
 
 antibodies were visualized with a
donkey anti–rabbit immunoglobulin conjugated with Texas red
(Amersham Corp. Arlington Heights, IL). For ICAM-1 immu-
nofluorescence analysis, lymph node T cells were isolated on mu-
rine T cell enrichment columns (R&D Sys. Inc., Minneapolis,
MN) according to manufacturer’s recommendation from v-
 
rel
 
and v-
 
rel/ikba
 
 transgenic mice. T cells were spun onto slides and
incubated at 4
 
8
 
C overnight with anti–ICAM-1 FITC-labeled
monoclonal antibody (PharMingen, San Diego, CA).
 
Flow Cytometric Analysis.
 
Single cell suspensions of spleens
bearing tumors were placed in RPMI 1640 medium supple-
mented with 10% FCS, 4 mM glutamine, 50 mM 
 
b
 
-mercapto-
ethanol, 50 U/ml penicillin, and 50 mg/ml streptomycin. Flow
cytometry was performed with a flow cytometer and cell sorter
(Epics Profile II; Coulter Corp., Hialeah, FL). Single cell suspen-
sions from 
 
ikba
 
 and v-
 
rel/ikba
 
 transgenic thymi and spleens were
prepared and analyzed for surface expression of CD4 (clone
H129.19), CD8 (clone 7D4), TCR-
 
a
 
/
 
b
 
 (clone H57-597), B220
(clone RA3-6B2), HSA (clone J11d), Mac-1 (clone M17/70HL),
and Gr-1 (clone RB6-8C5) as previously described (21). Mono-
clonal antibodies were obtained from GIBCO BRL (Gaithers-
burg, MD) and PharMingen.
 
Western Blot Assays.
 
Cytoplasmic and nuclear fractions from
thymocytes were prepared as previously described (22). Aliquots
of cytoplasmic and nuclear extracts (20 
 
m
 
g) were boiled in Laem-
mli buffer and run overnight on a 12.5% acrylamide-bisacryla-
mide (200:1) gel at 12 mA. Western blotting procedures and anti-
bodies have been previously described (23). The proteins were
transferred onto nitrocellulose membranes and transfer efficiency
assessed by Ponceau S staining. Purity of the nuclear extracts was
checked by incubating the membranes with an antiserum specific
for the cytosolic enzyme lactate dehydrogenase.
 
Cell Labeling, Lysis, and Immunoprecipitation.
 
Isolated thymocytes
were labeled for 2 h with 500 
 
m
 
Ci/ml of [
 
35
 
S]methionine (1,000
Ci/mmol) in DMEM lacking methionine and containing 10%
heat inactivated and dialyzed FCS. The labeling medium was re-
moved and the cells were washed with cold PBS and lysed on ice
by adding radio immunoprecipitation assay buffer (10 mM Tris-
HCl, pH 7.5, 0.5% Nonidet P-40, 150 mM NaCl). Cell lysates
were first cleared with a preimmune serum (3 
 
m
 
l) for 3 h and
then immunoprecipitated with specific antisera as previously de-
scribed (23).
 
Electrophoretic Mobility Shift Assay.
 
The palindromic 
 
k
 
B site
used for these assays has been previously described (23). Nuclear
extracts (3 
 
m
 
g) were incubated with 20,000 cpm 
 
32
 
P-labeled
probe, 3 
 
m
 
g poly (dI/dC) in buffer containing 20 mM Hepes, pH
7.9, 60 mM NaCl, 5 mM MgCl
 
2
 
, 1 mM dithiothreitol, 0.5 mM
PMSF, and 17% glycerol in 25 ml final volume for 15 min on ice.
Protein loading was checked by Oct 1 DNA-binding activity.
Complexes were separated on 5.5% native polyacrylamide gels
run in 0.25 
 
3
 
 Tris base, boric acid, EDTA buffer, dried, and ex-
posed to X-Omat AR film (Kodak, Rochester, NY) at 
 
2
 
70
 
8
 
C.
 
Semiquantitative Reverse Transcription Analysis.
 
Semiquantitative
PCR was performed as described previously (17). The PCR con-
ditions were established such that amplification of the cDNAs was
linearly dependent on the concentration of the corresponding
messenger RNAs (mRNAs). This was achieved by performing
the reactions in the presence of [
 
32
 
P]dCTP; due to the greater
sensitivity of autoradiography as opposed to ethidium bromide
staining, a relatively low number of PCR cycles was sufficient to
detect the amplified product. In this way, the cDNA concentra-
tion remained the rate-limiting factor throughout the amplifica-
tion procedure. Lymph node T cells derived from 
 
ikba
 
, v-
 
rel, and
v-rel/ikba transgenic mice were isolated on murine T cell enrich-
ment columns (R&D Sys. Inc.), and total RNA was prepared and
quantified by absorbance at 260 nm. 10 mg of total RNA were
used for cDNA synthesis using 1,000 U of reverse transcriptase
(GIBCO BRL). After cDNA synthesis, each sample was diluted
five times and 5 ml were taken for amplification with 25 cycles by
using  Taq polymerase in the presence of [32P]dCTP and se-
quence-specific primers. Specific oligonucleotides were obtained
from Stratagene Corp. (La Jolla, CA). One-tenth of the PCR
products were separated on 8% native polyacrylamide gels run in
Tris base, boric acid, EDTA buffer, dried, and exposed to X-Omat
AR film (Kodak) at 2708C.
Results
Generation of v-rel Transgenic Mice Overexpressing IkBa in
the Thymus. The transcriptional activity of Rel/NF-kB
family of proteins is regulated, in part, by their association
with inhibitory molecules (IkBs) that sequester them as in-
active complexes in the cytoplasm. IkBa is the predomi-
nant inhibitory protein in most cell types (5, 13–16).
We recently generated transgenic mice specifically ex-
pressing v-Rel in thymocytes (17). These animals develop
T cell multicentric aggressive lymphomas. To study the ef-281 Carrasco et al.
fect of IkBa on the transforming capability of v-Rel, we
produced double transgenic v-rel/ikba mice by crossing
transgenic mice expressing v-Rel with transgenic mice
overexpressing IkBa. Both transgenes are under the con-
trol of the mouse T cell–specific lck proximal promoter.
The expression of v-Rel and IkBa in thymocytes from
the double transgenic mice was assessed by immunoprecip-
itation (Fig. 1 A). These analyses demonstrate the associa-
tion of v-Rel complexes with IkBa (Fig. 1, lanes 1 and 3)
and show that there is an excess of IkBa protein that is not
associated with v-Rel (Fig. 1, lane 4). In addition, these
data show that under these conditions, IkBb, another IkB
inhibitory protein, is not associated with v-Rel, suggesting
that this molecule does not play a major role in the inacti-
vation of v-Rel complexes (Fig. 1 A, lane 2).
The levels of IkBa protein expression in v-rel/ikba dou-
ble transgenic mice was determined by Western blot with
whole protein extract prepared from transgenic thymocytes
and compared with the levels of IkBa protein expression in
wild-type, ikba transgenic, and v-rel transgenic thymocytes
(Fig. 1 B). The highest levels of IkBa protein expression
were detected in v-rel/ikba double transgenic thymocytes
(lane 4). This represents almost two times the amount of
IkBa present in ikba transgenic (lane 2) and v-rel transgenic
thymocytes (lane 3). As described previously, there is an in-
crease in the levels of IkBa in v-rel transgenic thymocytes
when compared with control thymocytes (lane 1) due to IkBa
protein stabilization by v-Rel–containing complexes (17).
IkBa Overexpression Changes v-Rel Nucleus/cytoplasm Dis-
tribution. To examine whether the overexpression of IkBa
in v-rel transgenic mice alters the nuclear–cytoplasmic dis-
tribution of v-Rel, we performed Western blot analyses us-
ing thymocyte extracts from wild-type, v-rel transgenic,
and v-rel/ikba double transgenic mice (Fig. 2 A). In v-rel
transgenic thymocytes, a significant amount of v-Rel,
z30% of the total protein, was localized in the nucleus
(lanes 3 and 4). In contrast, in v-rel/ikba double transgenic
thymocytes, .90% of the v-Rel protein is retained in the
cytoplasm, and only a small amount translocates to the nu-
cleus (lanes 5 and 6). The blot containing lanes 5 and 6 was
overexposed to detect the min amounts of v-Rel protein in
the nucleus. Incubation of the same membrane with antise-
rum specific for the cytosolic enzyme lactic dehydrogenase
demonstrated no cross-contamination of nuclear and cyto-
plasmic extracts (data not shown).
The changes in the nuclear/cytoplasmic distribution of
v-Rel protein in the double transgenics were further con-
firmed by immunofluoresence (Fig. 2 B). v-Rel protein in
v-rel transgenic thymocytes is detected in both nucleus and
cytoplasm; in contrast, in v-rel/ikba double transgenic thy-
mocytes, v-Rel is mainly detected in the cytoplasm (a and
b, respectively). In addition, the distribution of v-Rel and
IkBa proteins in transformed T cells from v-rel/ikba double
transgenic mice is also mainly in the cytoplasm (c and d, re-
spectively).
IkBa Overexpression Decreases p50/v-Rel Heterodimer, but
Not v-Rel Homodimer DNA-binding Activity. To investigate
whether the kB-binding activity was altered in thymocytes
of v-rel/ikba double transgenic mice compared to v-rel
transgenic mice, thymocyte protein extracts were analyzed
by electrophoretic mobility shift assays (EMSA) using a pal-
indromic kB site (Fig. 2 C).
The p50/v-Rel DNA binding activity in nuclear extracts
from v-rel/ikba double transgenic thymocytes presents a
dramatic reduction compared to nuclear protein extracts
from v-rel transgenic thymocytes (compare lanes 1 and 4).
However, the v-Rel/v-Rel DNA-binding activity remains
almost unchanged (compare lanes 2 and 5). The amount of
nuclear protein extract added to the DNA binding reaction
was controlled by measuring Oct 1 DNA-binding activity.
Oct 1 DNA-binding activity was comparable between the
different protein samples (data not shown).
These results indicate that v-Rel homodimers are signifi-
cantly less sensitive than p50/v-Rel heterodimers to the in-
hibitory effect of IkBa. The reduced affinity of v-Rel for
IkBa may be one of the key molecular basis for v-Rel
transformation.
IkBa Overexpression Extends Survival and Changes the
Clinical Expression of v-rel Transgenic Mice. To investigate the
consequences of the changes in kB binding activity in
v-rel/ikba double transgenic mice, a colony of these animals
was bred and their health status monitored over time in a
nongerm-free environment (Fig. 3). The v-rel/ikba double
transgenic mice presented a longer survival and appeared
completely healthy for a longer period of time when com-
pared with v-rel transgenic mice. The mortality curve dem-
onstrates that high levels of IkBa extended the survival of
v-rel transgenic mice (75% of v-rel transgenic mice suc-
cumbed before 25 wk of age, whereas 100% of the v-rel/
Figure 1. v-Rel/IkBa com-
plexes (A) and IkBa protein ex-
pression (B) in v-rel/ikba double
transgenic thymocytes. To gen-
erate v-rel/ikba double transgenic
mice,  ikba homozygous trans-
genic mice were crossed with v-rel
heterozygous transgenic mice.
Both transgenes were under the
control of the lck promoter.
Screening of double transgenic
mice was done by PCR analysis
using v-rel–specific oligonucle-
otides. (A) Immunoprecipitations
were performed as previously
described (31). [35S]methionine-
labeled thymocytes were lysed
under nondenaturing conditions,
and total protein extract was im-
munoprecipitated with anti–v-Rel
antibodies. The immunoprecipi-
tate was denatured to dissociate
the v-Rel–containing immune
complex and then reprecipitated,
first with IkBa and subsequently
with IkBb and v-Rel antibodies (left). The supernatant of the total pro-
tein extract treated with anti–v-Rel antibody was subsequently reprecipi-
tated with anti-IkBa and anti-IkBb antibodies (right). (B) The levels of
IkBa protein expression were analyzed by Western blot in total protein
extracts from control (w.t.), ikba transgenic, v-rel transgenic and v-rel/ikba
double transgenic thymocytes.282 v-rel Transgenic Mice Overexpressing IkBa
Figure 2. Change of nucleus/cytoplasm distribution of v-Rel in v-rel/
ikba double transgenic thymocytes. (A) Western blot analysis. Cytoplas-
mic (C) and nuclear (N) fractions from thymocytes and Western blot as-
says were performed as previously described (31). (B) Immunofluores-
ence. Thymocytes from 6-wk-old v-rel (a) and v-rel/ikba (b) transgenic
mice were spun onto slides, incubated with anti–v-Rel antibodies, and
visualized with donkey anti–rabbit Texas red–labeled antibodies. T cells
from spleen-bearing tumors of v-rel/ikba double transgenic mice were
spun onto slides, incubated with anti–v-Rel (c) or anti-IkBa (d) antibod-
ies, and visualized with donkey anti–rabbit Texas red–labeled antibodies.
(C) Decreased p50/v-Rel kB-binding activity in v-rel/ikba double trans-
genic thymocytes. Electrophoretic mobility shift assays were performed as
previously described (23) using nuclear protein extracts from v-rel and
v-rel/ikba double transgenic thymocytes. Lanes 1 and 4 were treated with
preimmune sera (p.i.), lanes 2 and 5 were treated with anti-p50 antibody
(a-p50), and lanes 3 and 6 were treated with anti–v-Rel antibody (a-v-Rel).
Figure 3. Overexpression of IkBa increases survival of v-rel transgenic
mice and changes the clinical expression. (A) Mortality curve. Deaths in
v-rel/ikba transgenic animals occurred at later times and were the result of
secondary opportunistic infection according to pathologic analysis and
microbiology. Autopsy, and histologic examination of v-rel/ikba trans-
genic mice revealed a less severe lymphomatous infiltrate than in v-rel
transgenic mice. n 5 29 for v-rel 35, and n 5 13 for v-rel/ikba. (B) T-cell
cutaneous lymphoma in v-rel/ikba double transgenic mice. All v-rel/ikba
transgenic mice developed skin lesions characterized by thickening and
exfoliative plaques. Arrow indicates a v-rel/ikba transgenic mouse; the
control mouse is an ikba transgenic littermate. (The lesions were never
observed in v-rel transgenic mice.)283 Carrasco et al.
ikba double transgenic mice were unaffected at that time).
Young v-rel/ikba double transgenic mice, between 3 and
10 wk old, appeared normal as assessed by habits, weight,
posture, and histopathology. However, all v-rel/ikba double
transgenic mice developed skin lesion in face, ears, tail, and
feet after 15 wk of age. These lesions, characterized by loss
of hair, thickening of the skin, and exfoliative plaques (Fig.
3 B) progressed slowly with no major compromise in the
health status of the mice. Evaluation for a longer period of
time revealed that v-rel/ikba double transgenic were sus-
ceptible to bacterial infections and that they succumbed
due to secondary infections by pathogens that colonize the
skin; antibiotic prophylactic treatment extended their sur-
vival for an additional 2–4 wk (data not shown). Autopsies
of v-rel/ikba double transgenic mice did not reveal massive
tumoral cell burden in lung, liver, lymph nodes, and
spleen, indicating that in contrast to v-rel transgenic mice,
massive tumor cellular infiltration was not the primary rea-
son for organ failure in the double trangenic animals (17).
T Cell Cutaneous Lymphoid Infiltrates in v-rel/ikba Double
Transgenic Mice. The earliest manifestation of disease in
most of the v-rel/ikba double transgenic mice was the ap-
Figure 4. Tumor pathology in
v-rel/ikba transgenic mice. Tissue
blocks were fixed in 10% neutral
buffered formalin and processed
for paraffin embedding. 5-mm
sections were stained with hema-
toxylin and eosin. Sections from
skin (a, b, c, and d), lung (e), liver
(f), spleen (g), and lymph node
(h) are shown. Arrow heads indi-
cate sites of lymphoid infiltra-
tion. Photomicrographs were
taken at 3100 (a, b, e, and f),
3250 (c and d), 312.5 (g and h).
E, epidermis; D, dermis; PA,
paracortical area; PT, portal triad;
RP, red pulp; WP, white pulp.284 v-rel Transgenic Mice Overexpressing IkBa
pearance of facial skin lesions that progressed slowly (Fig. 3
B). Light microscopy revealed cellular infiltration of the
dermis by large lymphocytes of irregular nuclei (Fig. 4, a–d).
Isolated foci of epidermal infiltration by tumor cells were
occasionally seen, but typical Pautrier’s microabcesses and
massive epidermal infiltration were not observed (Fig. 4 e).
The histologic appearance of this lymphoid infiltration re-
sembles one seen in cutaneous T cell lymphomas (24–27).
In contrast to v-rel/ikba transgenic mice, dermal compro-
mise was rarely seen in v-rel transgenic mice (17). Histopa-
thology of v-rel/ikba transgenic animals revealed much less
severe tumoral cellular infiltration in other tissues besides
skin (17). For instance, in the lung of v-rel transgenic mice,
tumoral cellular infiltration around bronchi and alveoli was
severe enough to cause organ failure. In v-rel/ikba trans-
genic mice, lung compromise was much less severe with
only tumoral cell infiltration around the bronchi, but not in
the parenchyma (17; Fig. 4 e). The liver in v-rel transgenic
mice was always enlarged and massively infiltrated by tu-
mor cells that frequently plugged the vessels and produced
extensive areas of ischemia and tissue necrosis. In contrast,
in v-rel/ikba double transgenic mice, the liver was not en-
larged, and lymphoid infiltration was seen in hepatic sinu-
soids and around the portal triad, but areas of necrosis were
not observed (Fig. 4 f). The spleen in v-rel transgenic mice
was dramatically enlarged with complete distortion of the
normal architecture and massive areas of tissue necrosis. On
the other hand, in v-rel/ikba double transgenic mice, the
spleen was moderately enlarged and remnants of the nor-
mal splenic architecture with demarcation of white and red
pulp areas were always present (Fig. 4 g). Lymph nodes in
v-rel/ikba double transgenic mice were not severely com-
promised, even at very late stages of disease, as was the case
in v-rel transgenic mice (Fig. 4 h, and data not shown).
Thymic atrophy was a constant observation in both v-rel
and v-rel/ikba transgenic mice (data not shown). These his-
topathological studies demonstrate that v-rel/ikba double
transgenic mice developed lymphoma, but the magnitude
of the visceral compromise was much less than in v-rel
transgenic mice of the same age. These results indicate that
IkBa overexpression does not prevent tumor formation,
but does delay the appearance of tumors, the progression of
the disease, and decreases the severity of the lymphomatous
state observed in v-rel transgenic mice. In addition, these
results indicate that IkBa overexpression induces transcrip-
tional changes in v-Rel–transformed T cells that resulted in
their increased tropism for the skin.
Flow Cytometric Analysis of Lymphoid Cells from v-rel/ikba
Double Transgenic Mice. To understand the changes in the
clinical expression of v-rel/ikba double transgenics com-
pared to v-rel transgenic mice, we analyzed lymphoid cell
populations by flow cytometry (Fig. 5). Flow cytometric
analysis of lymphoid cells in v-rel transgenic mice have
been previously described (17). Analyses of thymuses and
spleens from young v-rel/ikba double transgenic animals
(3–8 wk) did not reveal any alterations when compared to
ikba transgenic littermates (Fig. 5 A, a–d, and data not
shown). ikba transgenic littermates were used as a control,
since no differences in lymphoid populations have been de-
tected in ikba transgenic mice when compared to wild-type
animals (Perez, P., unpublished results and data not shown).
Analysis of spleens from moribund and euthanized v-rel/
ikba double transgenic animals showed an expanded T cell
population characterized by intermediate and low levels of
the TCR a and b chains (Fig. 5 B, a and b). In addition, a
striking difference between v-rel transgenic and v-rel/ikba
double transgenic mice was a significant increase in CD81
single positive T cells in v-rel/ikba transgenic mice, a popu-
lation of cells that was not always increased in v-rel trans-
genic mice. These results indicate that IkBa overexpression
in v-rel transgenic mice alters the developmental profile of
the v-rel transformed T cells, allowing the T cells to reach a
more mature phenotype. Only a moderate increase of T
cells coexpressing markers associated with an immature
phenotype (HSA) was detected in the double transgenic
(Fig. 5 B, e and f), in contrast to the dramatic changes that
we previously observed in v-rel transgenic mice. An in-
creased population of granulocytes as a result of infection
was detected in v-rel/ikba double transgenic mice (Fig. 5 B,
g and h).
v-Rel–containing Complexes Have Lower Affinity for IkBa
than Dc-Rel–containing Complexes. To understand why higher
levels of IkBa are required to reduce nuclear translocation
of v-Rel and p50/v-Rel kB-binding activity in transgenic
thymocytes, we compared the inhibitory effect of IkBa on
kB binding activity in nuclear protein extract derived from
Figure 5. Flow cytometric
analysis in v-rel/ikba transgenic
mice. (A) Flow cytometric analysis
of CD4 and CD8 surface mark-
ers in thymocytes from 6-wk-old
ikba (a and c) and v-rel/ikba (b and
d) transgenic mice. (B) Flow cy-
tometric analysis of surface markers
in splenocytes from 6-mo-old
ikba (a, c, e, and g) and v-rel/ikba
(b, d, f, and h) transgenic mice.
Flow cytometry was performed
using a flow cytometer (Epics
Profile II) and cell sorter (Coulter
Corp.). Single cell suspensions
from thymocytes and splenocytes
were prepared and analyzed for
surface markers expression of
CD4, CD8, HSA, TCR-a/b,
B220, Mac-1, and Gr-1 as previ-
ously described (8).285 Carrasco et al.
v-rel transgenic (Fig. 6 A) and Dc-rel transgenic thymocytes.
Dc-rel transgenic animals express a truncated version of the
mouse c-Rel protein (Dc-Rel) under the control of the lck
promoter, and, like the v-Rel oncogenic protein, lacks part
of the COOH-terminal transcriptional activation domain
keeping the RHD intact. The generation of Dc-rel trans-
genic mice has been previously described (17). Increasing
levels of purified baculovirus expressed IkBa protein were
added to identical amounts of nuclear protein extracts from
Dc-rel transgenic thymocytes (Fig. 6 A a) and v-rel trans-
genic thymocytes (Fig. 6 A b) before starting the kB-bind-
ing reaction. The total amount of protein extract used in
the reaction was tested by Oct 1 DNA-binding activity and
the identification of the complexes by antibody supershifts
(data not shown). In the absence of added IkBa, similar
amounts of total kB binding activities were detected in Dc-
rel transgenic (Fig. 6 A a, lane 1) and in v-rel transgenic thy-
mocytes (Fig. 6 A b, lane 1). However, when increased
amounts of IkBa protein were added to the binding reac-
tion, the binding of p50/Dc-Rel was dramatically reduced
(Fig. 6 A a, lanes 2 and 3), whereas the binding of v-Rel
containing complexes was slightly affected (Fig. 6 A b, lanes
2 and 3). At 100 ng of IkBa, the binding of v-Rel–con-
taining complexes is significantly reduced (Fig. 6 A b, lane
4), and only when the highest amounts of IkBa were used
(1 mg) and when endogenous p50/p50 kB binding also be-
gan to be affected (Fig. 6 A a, lane 5), was the binding of
v-Rel–containing complexes completely reduced (Fig. 6 A
b, lane 5). These results demonstrate that the binding of
v-Rel–containing complexes is more resistant than the
binding of complexes containing the cellular homologue
Dc-Rel to the inhibitory effect of IkBa, and offer an attrac-
tive explanation for the molecular mechanisms involved in
the transforming activity of v-Rel. This is in agreement
with previous in vitro studies that demonstrated a reduced
IkBa inhibition of DNA binding by the oncogenic v-Rel
protein when compared to the nononcogenic c-Rel pro-
tein (28).
Increased Levels in the Expression of a Cell Adhesion Molecule
ICAM-1 in v-rel/ikba Double Transgenic Thymocytes. To cor-
relate  the changes in the clinical expression and the cutane-
ous infiltration observed in v-rel/ikba double transgenic
mice, we examined the level of expression of kB respon-
sive genes encoding adhesion molecules that may be in-
volved in the increased tropism of v-rel/ikba double trans-
genic T cells for the skin (22, 24–27, 29, 30). We analyzed
mRNA expression levels of ICAM-1 by reverse transcrip-
tion PCR in ikba, v-rel, and v-rel/ikba transgenic T cells
(Fig. 6 B). cDNA was prepared from total mRNA ex-
tracted from single cell suspension from ikba normal lymph
nodes and from v-rel and v-rel/ikba tumor-bearing lymph
nodes. The cDNA was amplified with 25 PCR cycles in
the presence of [32P]dCTP and the appropriate pairs of spe-
cific oligonucleotides. The same amount of total mRNA
was present in all the samples, as demonstrated by equal
amounts of b-actin PCR products (Fig. 6 B). By compar-
ing the amount of PCR products detected in ikba (lane 1),
v-rel (lane 2), and v-rel/ikba lymph node–derived T cells
(lane 3), it is evident that there is a dramatic increase in the
expression of ICAM-1 in v-rel/ikba transgenic T cells. No
major changes in the expression of vascular cell adhesion
molecule 1 and dorsal midline–globulin-restricted axonal
surface protein were detected between v-rel and v-rel/ikba–
transformed T cells (Fig. 6 B and data not shown). Increased
levels of ICAM-1 expression in v-rel/ikba transgenic T cells
were also detected on cytospin preparation by indirect
immunofluorescence using anti–ICAM-1 FITC-labeled anti-
body (Fig. 6 C). The difference in the level of ICAM-1 ex-
pression between v-rel and v-rel/ikba may explain the in-
creased tropism for the skin of v-rel/ikba–transformed T cells.
Discussion
In this work we have demonstrated that overexpression
of the Rel/NF-kB inhibitory protein, IkBa, delays the de-
velopment of T cell lymphomas in a transgenic mouse
model that expresses the oncogenic v-Rel protein under
the control of the lck T cell–specific promoter (17). Previ-
ous studies indicate that v-Rel transformation requires its
Figure 6. Reduced IkBa in-
hibition of v-Rel DNA binding
activity (A) and increased levels
of ICAM-1 in v-rel/ikba double
transgenic T cells (B and C). (A)
Equal amounts of nuclear pro-
tein extracts from Dc-rel ( a ) or
v-rel ( b ) transgenic thymocytes
were incubated in the presence
of increased amounts of IkBa
protein and analyzed by EMSA
using a palindromic kB-binding
site. (B) Total RNA was pre-
pared from ikba transgenic, v-rel
transgenic or v-rel/ikba double
transgenic lymph node–derived
cells. After cDNA synthesis,
one-tenth of the reaction mixture was amplified in the presence of 0.1 mCi of [32P]dCTP using Taq polymerase and sequence-specific primers. One-fifth
of the amplified products were separated on 6% nondenaturing polyacrilamide gels. Gels were dried and exposed to x-ray film. (C) Purified T cells from lymph
nodes of v-rel transgenic (a) and v-rel/ikba (b) double transgenic mice were spun onto slides and incubated with anti–ICAM-1 FITC-labeled antibody.286 v-rel Transgenic Mice Overexpressing IkBa
translocation to the nucleus and binding to a set of specific
Rel/NF-kB responsive genes (1–5).
Role of IkBa in v-Rel Transformation. Previous studies have
suggested a potential tumor supresser activity for IkBa (4).
IkBa-deficient mice displayed elevated levels of nuclear
Rel/NF-kB activity in hemopoietic tissues. Unfortunately,
these animals do not survive long enough for evaluation of
appearance of lymphoid malignancies (31, 32).
In this work, we have demonstrated that although v-rel/
ikba double transgenic thymocytes expressed IkBa protein
at very high levels, there was still some nuclear v-Rel pro-
tein in the double transgenic cells, suggesting an intrinsic
ability of v-Rel to escape the inhibitory effect of IkBa.
This observation was correlated with an increased resis-
tance of v-Rel DNA-binding activity to the inhibitory ef-
fect of IkBa when compared to a truncated version of c-Rel
that lacks the transcriptional activation domain. The re-
duced affinity of v-Rel for IkBa may be associated with
some of the internal mutations present in the Rel homol-
ogy domain of v-Rel (1–5). It is noteworthy to mention
that transgenic mice overexpressing either RelA or RelB in
T cells under the control of the lck did not develop lym-
phomas. In the case of rela transgenic mice, the absence of
tumor formation was correlated with the fact that there was
no increased DNA-binding activity in T cells, because
RelA protein was efficiently retained in the cytoplasm by
IkBa (19). However, relb transgenic thymocytes presented
a dramatic increase in DNA-binding activity due to the fact
that RelB complexes were not efficiently retained in the
cytoplasm because of their low affinity for IkBa (33), indi-
cating that increased nuclear levels of Rel/NF-kB activity
appear to be insufficient for transformation. Therefore, to-
gether with the low affinity for IkBa, it appears that v-Rel
possesses additional and unique properties that render a po-
tent transforming potential in mammalian cells.
The fact that IkBa overexpression extended the survival
but did not prevent tumor formation in v-rel transgenic
mice indicates that it would be impossible to achieve in
vivo the levels of IkBa required to compensate for the re-
duced affinity of v-Rel for IkBa to prevent v-Rel transfor-
mation.
ICAM-1 Overexpression in Lymphoproliferative Disorders.
When nuclear kB-binding activity was assessed by EMSA
in v-rel/ikba double transgenic thymocytes, the most strik-
ing observation was the dramatic reduction in the p50/v-Rel
DNA-binding activity with almost no change in v-Rel/
v-Rel DNA binding activity. The reduction in the p50/
v-Rel DNA binding correlated with the changes observed
in the clinical expression of v-rel/ikba double transgenic
mice, and supports our previous indications that v-Rel may
be active as a p50/v-Rel heterodimer and as a homodimer
(17), with the p50/v-Rel heterodimeric form being more
susceptible to IkBa inhibition. Because of the changes in
the clinical expression and the differences observed in p50/
v-Rel and v-Rel/v-Rel DNA-binding activity in v-rel/
ikba double transgenic T cells, it is possible to speculate that
v-Rel either as a heterodimeric complex with p50 or as a
homodimeric complex may target different sets of kB-reg-
ulated genes. An example of this differential regulation is
the observation of increased levels of ICAM-1 in T cells
derived from v-rel/ikba double transgenic mice, but not in
T cells derived from v-rel transgenic mice. Interestingly,
strong induction of ICAM-1 has been observed in human
lymphoproliferative disorders (29, 34), and ICAM-1 over-
expression in v-rel/ikba double transgenic mice may be re-
sponsible for the increased tropism of T cells for the skin
observed in these animals (25, 22).
Rel/NF-kB Activity in Cutaneous T Cell Lymphomas.
The lymphomatous infiltration observed in v-rel/ikba trans-
genic mice resembles that seen in T cell cutaneous lympho-
mas: the Sezary syndrome, mycosis fungoides, or other re-
lated disorders (35). Our observation that v-rel/ikba double
transgenic mice developed cutaneous T cell lymphomas is
particularly interesting in light of the observation that chro-
mosomal translocations associated with structural alterations
of the Rel/NF-kB family of proteins have been docu-
mented in several cases of T cell cutaneous lymphomas in
human patients (26, 35–40). In particular, rearrangement
and altered expression of the NFKB-2 gene have been
identified in the HUT 78 human cutaneous T cell leuke-
mia line (39, 40). In addition, structural alterations of the
NFKB-2 gene have also been identified very commonly
(14%) in neoplasms derived from mature T cells such as
mycosis fungoides and Sezary syndrome (24, 38). These
structural alterations may contribute to lymphomagenesis
by determining a constitutive activation of the NF-kB sys-
tem and, in particular, of NFKB-2 target genes (36, 37).
This data, in addition to our observations, strongly supports
the notion that structural alterations of other Rel/NF-kB
family members may play a role in lymphomagenesis. Fur-
thermore, our results indicate that variations in the clinical
expression of lymphoid malignancies such us mycosis fun-
goides and Sezary syndrome may be based on subtle
changes in the nuclear composition and interplay among
the different Rel/NF-kB and IkB molecules. In this sense,
v-rel and v-rel/ikba transgenic mice constitute a potential
model to study the molecular mechanisms involved in the
generation of lymphoid malignancies.
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